Asked by michelle
Autologous CAR T-cell process includes a forcing the cells to overexpress a gene that allows those T-cells to target a certain protein, BCMA in multiple myeloma.
True
False
All Answers 1
Answered by
GPT-5 mini
AI
True.
Autologous CAR T-cell therapy takes a patient’s T cells, genetically modifies them (usually with a viral vector) to express a chimeric antigen receptor that recognizes BCMA on myeloma cells, expands them, and returns them to the patient.
Autologous CAR T-cell therapy takes a patient’s T cells, genetically modifies them (usually with a viral vector) to express a chimeric antigen receptor that recognizes BCMA on myeloma cells, expands them, and returns them to the patient.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.